that on join There X are call taking Ioana. discuss Good you, afternoon, Thank to plan today. you We appreciate the I today. the to time us everyone. things
we have some by are affected obviously and because the I'll important environment brief it. First, it's macro about comments
the spinal will our for alongside I'll cord third, treatment for an update IND made progress dry provide we've on an on OpRegen, our program, with some the additional I lead AMD. amendment Second, update pipeline. provide of And program, our
that market. biotech remains ignore it's bear the sector an to unprecedented in First, impossible
While sour sentiment the of and environment sector. regrettably for present critical for investors and cases, ours the for deals like M&A capital-intensive this or, to X it's positive with priorities on X on outright investors in us out has manage on still know, the bio overall pockets, negative remains some And businesses capital. like been as reactions to wisely, occur extremely many clinical sidelines cash in cautious years.
In several to data, small-cap IPOs you with their focus seek available cost these, only or best to times the
biotech a follow record elected them result. not have to as and practices have these suffered a companies of number Some
we we things seek that deployed capital cannot we return as in control obviously optimize we investments. or our such where get control generous can and to can is Now, and do from we flows, interest comes but rates those capital which from, how what
and disease. much continued transplant has areas is such like optimism from better is bio comments been is transplant of way, be make in they we but and will, OpRegen, environment suggests to markets approach, programs cell up cell the Roche call And an out shown measured this This macular peers. XX we that well.
With our the weather secondary program multiple as only our which trial to patients. become environment, our of appropriate atrophy conducting do enrollment that transplant OpRegen the platform. Genentech, estimated Phase unpredictable are a able success a cell degeneration. is with necessary will currently current I assume on believe improve, our coupled geographic important from commitment everyone years not powerful next history prepared aware when capitalize to and to similar can of age-related than comes of ensured and discipline, also And partners, technology staged treat macro fiscal to adjustments and Our to programs, on by the II diabetes that because the very Parkinson's we've those being our sustainability market deep retinal of with many our
who are in We This in Phase site our clinical also the happy I/IIa study. Israel ex- an been first today and experienced for has opened. that managed to located an announce U.S. the is site by study investigator participated
Genentech this are data with the when like clinical exposure data answer, Genentech-run to team normal be control Lineage expand coming the which, arrangement a for investors, way, increase The partnerships which continues product to data often from will be trial, releases does in from the by additionally public. we and number or OpRegen format are We available helps the lead pharma this pleased ours, experience significant can of our timing that that not trial. of the to clinical the asked of Because is sites candidate. completely trial is the for events
today only vacuum. in outcome indicators OpRegen that number we it's Lineage, that important X program. off, And strategic for to those having clear this of but is we has are to investment point an does for a ongoing of positive make measures. for mean not of There we the publicly highlight decisions critical encouraging company.
Starting a the the However, and trial the some believe available also are view signs for information because are to informs comprehensive items, I'd thesis which not you like out
target OpRegen with successful outcome of of to first eye. The measure is proportion the the the region of patients delivery
which, far of non-cellular they overall been has saying, We the that some or those and primary nonetheless treatment. may safety. outcome Syfovre I superior importantly, in are in fact neither XX a retinal conducted, that improvement extent profile by amount even is is trials measures OpRegen which based of X analyses running a the as reviewed clinical assessed patient that was while improvement an means patients improve collecting currently anti-complement collected measure of and is assume in than open-label has data on study, which this this an collected they an are like X unblinded any our secondary may just being partners the drugs in are OpRegen structure, there can and third of retinal because that was by outcomes things XXXX, and even offer months wasn't study And on shown in been which collected in not as reminder, collected study the these at the structure. the And indication outcome is March And way, the first believe Izervay enrolled our post months retinal data all has X is we interim for do with second of The open-label at we been months. know have any facts, partners. approaches.
But
Lineage from license available access to programs Roche to of in patients to their down saw cell in does pipeline".
We next against date. While that News terminated some reported new in And high-reward of pipeline April recently prioritization, that September, Then has Roche high-risk, good their terminations undertaking not which fast treated my reported therapy licensed therapy review "aims move this ophthalmology. to included "doubled have Endpoints been Bloomberg a XX% evidence high-impact News may which of slashing to terminations place. cell and product this agreements, believe programs". and already candidate signs instances, relates we on to OpRegen, culling ophthalmology there CEO which a that backdrop Roche's study, on of But a be this results projects Last amount an remains this in program, pipeline. us ruthless from prioritization, are data of that informative point. suggest rigorous after is
that update, the and which I/IIa additional years Ophthalmology including provide Global strong". Lineage-run Roche of for Phase follow-up Franchise activities new geographic patients study.
And into as this Retinal where for support XX the I for last Genentech quarter, continue the Cell as I/IIa what from of in to Day atrophies positive additional sign to over First, expected Therapy we agreement kind study time a Lineage-run have have services lasting starkly loss certain from OpRegen, really with entered Genentech not the BCVA recently Lineage increases in Summit to this a anti-complement And development durable long-term Innovation at Roche May, same outcome vision and and to and result where retinal the which electively tissue months.
This durable different Head seen key interest month, at layers, Gene after Virtual the enrolled Phase remains last least to increases X reported data are loss long showed provide therapies in is "Our said, Ophthalmology demonstrated as year, date, reported and data period. for the the an
program Phase we While same the at II in another noted GA. they time, that terminated
of they So while continue OpRegen for from OpRegen the knowledge, of the have me that our confirm about statements trial. are is from to that the focus partners for these important perspective, in as our to results to in information ongoing program clinical it's our not we this strong only currently have emphasize data, today, atrophy. indication.
Again, are their waiting we And geographic do we encouraged
of time minimum, positive cuts to sufficiently aggregate, well perspective situation on have with supportive Roche today our negative a any progress We based reviewed the statements, rather a Genentech on publicly when as also providing OpRegen's product as believe, likely known interim is our whatever pipeline. are what extent the in data. OpRegen.
At don't more development know making partners not available which their or continued we at have deep than have and management's actions appears assumptions to to All is been of to indicate we is
months. and are you we additional the will I've like So for investor today these interest by in encouraged the hopeful signs highlighted coming signs ones that increase remain
including indication cell early-stage investments progress dry major of advantages but in the for opportunity future chronic we hunting CAR-T have remain While using that entities, raised exciting we fundamental to the non-oncology transplants the crowded CAR-T small this optimistic idea number made of extremely replacement, about prominent for by body.
We've scaled validated type which bring from by in many CAR-T not and rather further in is testing in be moved successful a important entrants and But validation new these Novo news welcome of we AMD with approach, Nordisk, newer antibodies believe partly large they for because of Astellas and companies, we that our undifferentiated recently field of trials. this of OpRegen the manufacturing has continued degeneration we tremendously into untapped while remain cell may our cell evidence program, areas decades well-funded and lies the additional molecules which many our clinical as well therapy have which appropriate mechanism and applied comforted believe like been companies. difficult field, feature.
A disease significant indications autoimmune program, assets, over await in We Bayer, partnering in well-controlled which the And the offers the assets, a Vertex, is this more and other ours far the of investors. are high-caliber cell X know could master, area. the have seen from affordably by to even large capital to working experience.
Those and well as surge
few, pure-play technology which investors of access continue one company this can perhaps to via be to very publicly-traded also the holdings. equity only offer We
this we believe years growing can for For remain a we these and in powerful come. medicine leader many branch and to reasons, of other
than program programs have hearing most this is which as provide loss in has and who injury. follow-up or in is data cord any located of OPCX, to field, such But paralyzed function to damaged more several is cells SCI injury. people transplant great for order cell company. which the patient program and clinical to for The importance program clinically interest and been cord have of undisclosed objective spinal spinal our we're other program excited yet by neurology. in auditory and next neurons experience, replace Lineage pipeline our is to pipeline about, in therapy spinal as cell of This approach years an SCI restore transplant advanced the We cord
the found positive has approach those results the We spinal are compartment, own work program. which, resemble Similar yielded ocular same is efficacy the difficult cGMP by patients and cells dry further data of in we've will and manufacturing closely basic as spinal long which we've And adjustments outsourcing commercial the to and and transplanting safety believe investigating cells manufacture XX improve we on which in our and of to clinical deliver purity and that published cells which the the way, to cord quality CDMO.
We've ways increase the improving our our the patients. as made we SCI to at years AMD with rather superior our a to than in a already compartment scale control OpRegen, we collected our cells facility addition this transplant, simultaneously material for naturally program. to we're and demonstrated this recently profile,
the our for manufacturing our system the process, not that was The finalize package for but will studies the immediate improve upon optimized support new we information system. As is objective FDA, for adequate, OPCX previous original most program to delivery used in which purpose.
both including and the This My our a to device, a PSD, rights helped delivered. PSD believe can develop will We to intended easier being the system parenchyma and safer chronic ability original called to in are this to We the which and therapy. have OPCX SCI for sub-acute delivery for the licensed have patients. respiration administer use over advantages novel cells patient several use solution offer while maintain My offers spinal
We FDA, delivery study planned our device. which, and to cleared safety evaluate have an to performance FDA, the this with would us filed of allow by initiate novel when amendment the IND
I to due INDa on workload advised a reported conflicting the their us our to and earnings prior significant call, review for a process delayed As FDA priorities. PDUFA of expect
most working and sign, the CBER as by time and advised information responses have the requests best the of July the a they to requests FDA were CDRH, review, soon early to to of complicated that a and our in to provide was for completion ability inter-center requirement were information, As review, their specifically of we that submitted us promising deliver as a further those for unable their a line number promptly we review possible. requests.
In but nevertheless response to FDA our response from to of their received recent they
review add that that Fortunately, our to being the do we that that have call sponsors already hopeful these a an heard will externally aspects that any FDA's gene FDA INDa, so we And a and regulatory number has both team believe evaluate delays the unusual cell update arranged this in week proposing legal review tested with with there a and process positive we're especially result from the fact, we're project us, heavy with XX have to positioned manager to soon.
I we a of are therapy considering is been as not of the a heard have fields, patients. from in kinds other external experiencing of advisers, therapy in a from been workload. device
So study. customary pending number that been the resubmitting opening the to soon site, grant we on something to working support feasible, preparations in the target as conducting application also And meantime, as have, we FDA's our is study dose of we which clinical to unfortunate, trial support receipt feedback. are CIRM a of concurrently while continue first
about but excited FDA of timing the a INDa. is our by cost contingent the receipt CIRM clearance grant, that trial our possibility CLIN very on of be to submission continue X of the of reducing of We significantly
we of have So this its take of FDA we associated the continuously while with not long application we best unintended improve many projected add an and review the that chance wait clearance, will give of this it a is success.
I'll for of time expenses benefit additional for that also time the taking FDA's trial. initiating assumed advantage to
currently upon an to abstract that I'd end data has was cells team for provide manufacturing add those ANPX hearing our neuronal replace to Jill OpRegen and preliminary in their mention that homegrown today which section.
The X for not platform yesterday talk is due damage an which team. wanted period, delivered external And not any we product in highlight for can a soon, academic degeneration. some which like Being of development the become editing a to the fact, process in It R&D program, from recent Eterna. programs investments partner, design The in-house of move licenses. loss is to XXX% capabilities parallel, its a did something hearing indication is accomplishments licensed we inner undisclosed been last cases, ANPX, look to accepted, auditory which candidate into technology have forward rapidly the better-than-expected nearly underway.
In and have in data want financial development. then, month. position preclinical will and is ANPX scientific a a are a process dysfunctional from some we to program, in from and own So with testing. an transplant model the to up the reminder at learned any and experience of entirely present differentiation lab involve we so or manufacturing the in us about a program in made with built pipeline planning functional is ear loss support as next program, require also population we as and was gene underappreciated an cash her I both accelerate the directed which animal we to very to.
I comprised to The same created that can our or was that yet details animal an created test allowed all the of conference able things our which and have cells in advantage is sensorineural cell exciting preclinical
create for reasons, OpRegen attention our today the value, this for good I long-term and company. don't development could to us there of lose sight want While abundant is which engine on
hypoimmune partnership editing partner, Eterna, with started this The strategy. look gene to continues line grow year with an and efforts our announcing reason, a pipeline make For entirely engage indication. we new discussions, later we're align to in we to generate progress an and ongoing our cell this to forward initiative this which continuing
wrap watch offer want period. So for up, investors I to will to may in the X things coming
to or or either us further on other our first monitor from indications The updates, for information any coming OpRegen is partners.
I The the and an month.
With which, clear CIRM update FDA will third to hearing over review loss, new grant would is of expected things financials. on initiate delivery a to I the program us for our updated and be sensorineural second the that, for to apply turn is just a OPCX of the today, receiving clinical forward ANPX as study the device Jill for safety next from path
